1369 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Shah
    Shah
  4. Sauter
    Sauter
  5. Palomba
    Palomba
  6. Goldberg
    Goldberg
  7. Halton
    Halton
  8. Brentjens
    Brentjens
  9. Chen
    Chen
  10. Moskowitz
    Moskowitz

Groups

  1. Advanced Practice Providers (1369)
  2. Nursing (1108)
  3. Department of Medicine (653)
  4. Survivorship Research (513)
  5. Center for Hematologic Malignancies (339)
  6. Epidemiology and Biostatistics (328)
  7. Hematologic Malignancies, Division of (327)
  8. Solid Tumor Oncology Division (324)
  9. Population Sciences Research Program (261)
  10. Biostatistics Service (257)
  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (694)
  2. Journal Article (538)
  3. Review (51)
  4. Book Section (36)
  5. Editorial (16)
  6. Research Letter (14)
  7. Miscellaneous (10)
  8. Conference Paper (4)
  9. Correspondence (4)
  10. Book Whole (1)
  11. Guidelines (1)
Groups
  1. Advanced Practice Providers (1369)
  2. Nursing (1108)
  3. Department of Medicine (653)
  4. Survivorship Research (513)
  5. Center for Hematologic Malignancies (339)
  6. Epidemiology and Biostatistics (328)

More Groups

People
  1. Sergio Giralt (98)
  2. Miguel-Angel Perales (77)
  3. Gunjan Shah (68)
  4. Sean Devlin (68)
  5. Craig Sauter (63)
  6. Maria Palomba (61)

More People

Years
  1. 2025 (29)
  2. 2024 (103)
  3. 2023 (92)
  4. 2022 (114)
  5. 2021 (101)
  6. 2020 (101)

More Years

Publications
  1. Journal of Clinical Oncology (170)
  2. Oncology Nursing Forum (117)
  3. Blood (114)
  4. Biology of Blood and Marrow Transplantation (59)
  5. Clinical Journal of Oncology Nursing (47)
  6. Annals of Surgical Oncology (36)

More Publications

Publishers
  1. American Society of Clinical Oncology (192)
  2. Elsevier Inc. (190)
  3. Oncology Nursing Society (ONS) (169)
  4. American Society of Hematology (121)
  5. Lippincott Williams & Wilkins (91)
  6. Springer (70)

More Publishers

Results (1369)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax
    Meeting Abstract

    Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Timing and immune status after cellular therapies predict response to COVID-19 vaccines
    Meeting Abstract

    Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantifying intrathecal drug delivery utilizing programmable ventriculoperitoneal shunts
    Meeting Abstract

    McThenia, S.; Pandit-Taskar, N.; Grkovski, M.; Donzelli, M.; Diagana, S.; Greenfield, J.; Souweidane, M.; Kramer, K.
    Neuro-Oncology Advances (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save